Applications of 4-Chloro-D-Phenylalanine Methyl Ester Hydrochloride in Industrial Manufacturing

4-Chloro-D-Phenylalanine Methyl Ester Hydrochloride is a specialty amino acid derivative recognized for its utility in advanced industrial synthesis, particularly where enantiomerically pure intermediates are required. Our production focuses on meeting the unique demand profiles of pharmaceutical, peptide, agrochemical, and diagnostic sectors. Below, we document the precise downstream applications, standards, formulation strategies, process points, and end-products associated with this material.

1. Chiral Building Block in Peptide Synthesis

Pharmaceutical and biotech manufacturers rely on this material when producing complex, enantiomerically pure peptides where the 4-chloro motif introduces distinct conformational or pharmacokinetic properties. The methyl ester group serves as a temporary protecting group during solid-phase or solution-phase peptide assembly, facilitating selective deprotection in multi-step synthesis.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP <823> Radioactive Drugs for Positron Emission Tomography–Compounding
• European Pharmacopoeia, Amino Acids for Peptide Synthesis (Ph. Eur. 09/2022:1161)
• FDA 21 CFR Part 210/211 cGMP for Finished Pharmaceuticals

Typical usage ratio

• Peptide assembly protocols typically dose this intermediate at a 1:1 to 1:1.2 molar ratio relative to the adjacent amino acid, with actual charge adjusted for resin loading, target sequence length, or side-chain protecting group compatibility.

Downstream process integration

• Material is introduced at the amino acid coupling step, either in manual or automated peptide synthesizers, using standard coupling reagents such as HATU, DIC, or PyBOP under controlled temperature and solvent conditions to ensure chiral fidelity and minimal racemization.

Final product types

• Therapeutic peptides (e.g., modified hormone analogues, antimicrobial peptides)
• Peptide-based imaging agents
• Research-grade oligopeptides and polypeptides
• Precursor fragments for biopharmaceutical APIs

2. Intermediate for Non-Natural Amino Acid API Synthesis

This compound plays a critical role in the manufacture of active pharmaceutical ingredients incorporating non-natural amino acid motifs, especially those requiring a 4-chloro substituent for receptor binding or altered metabolic profile. Its high enantiomeric excess minimizes downstream purification, directly impacting API quality outcomes.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• Japanese Pharmacopoeia 18th Edition: General Monograph for Amino Acids
• FDA DMF (Drug Master File) referencing requirements
• WHO GMP: Active Pharmaceutical Ingredients

Typical usage ratio

• The ester is consumed as a key intermediate at 0.9–1.3 equivalents relative to other coupling partners; the precise amount depends on coupling efficiency, desired yield, and scale-up losses during isolation and purification.

Downstream process integration

• Material is introduced during the API’s backbone construction phase, often via ester hydrolysis followed by amidation or reductive amination steps, with subsequent purification by HPLC or crystallization to ensure batch homogeneity and regulatory compliance.

Final product types

• Investigational and commercial APIs featuring C4-halogenated phenylalanine units
• Protease inhibitors with enhanced resistance to metabolic degradation
• Pharmaceutical reference standards for bioanalytical testing
• Pharmacologically active peptides for clinical trials

3. Scaffold for Agrochemical Discovery and Synthesis

Agrochemical R&D labs select this methyl ester as a chiral scaffold to generate libraries of novel herbicides or insecticide candidates. The 4-chloro substitution often imparts desirable bioactivity, and the esterification eases subsequent derivatization. Its stereochemical purity is critical for reproducible biological activity screening.

Industry compliance standards

• OECD Guidelines for the Testing of Chemicals (Bioaccumulation, Degradation)
• FAO/WHO Specification and Evaluation of Agricultural Pesticides
• European Union Regulation (EC) No 1107/2009 on Plant Protection Products
• ISO 9001:2015 Quality Management for Agrochemical Intermediates

Typical usage ratio

• Employed at 1–5% of total synthetic mass in early-stage library synthesis, with scale-up batches adjusted based on LC-MS assay results and potency optimization studies.

Downstream process integration

• Compound enters at the heterocycle introduction or halogenation phase, after which subsequent functionalization may employ catalytic hydrogenation, Suzuki coupling, or amide bond formation to generate target molecules for bioassay screening.

Final product types

• Lead agrochemical candidate molecules for structure-activity relationship (SAR) studies
• Chiral auxiliaries in crop protection active ingredient synthesis
• Library compounds for insecticide and herbicide discovery
• Reference standards for analytical method development

4. Reagent in Diagnostic Peptide Marker Manufacture

Manufacturers of clinical and preclinical diagnostic reagents leverage this ester for assembling labeled peptide markers, where its high purity and chiral stability are essential for quantifiable detection. The 4-chloro group enhances conjugation site selectivity, crucial for assay reproducibility in immunoassays or mass spectrometry standards.

Industry compliance standards

• ISO 13485:2016 Medical Devices–Quality Management Systems
• CLSI C24-A3 Statistical Quality Control for Quantitative Measurement Procedures
• FDA 21 CFR 820–Quality System Regulation for In Vitro Diagnostic Devices
• EN 13612:2002 Performance evaluation of in vitro diagnostic medical devices

Typical usage ratio

• Formulators charge the ester at 0.95–1.05 molar equivalents per unique sequence position, with adjustments based on detection limit studies and label conjugation efficiency.

Downstream process integration

• Compound enters at the automated peptide synthesis or solution-phase assembly stage, with subsequent conjugation to reporter groups (such as fluorescent dyes or isotopic labels), followed by purification using reverse-phase HPLC to meet diagnostic grade specifications.

Final product types

• Labeled peptide calibration standards for clinical diagnostics
• Synthetic peptide antigens for ELISA and immunoassay kits
• Mass spectrometry peptide standards
• Quality control peptides for laboratory automation systems